Screening method of anti-myocardial fibrosis drug

Abstract

The invention discloses a screening method of an anti-myocardial fibrosis drug. The screening method specifically comprises the following steps: obtaining a known marker gene of myocardial fibrosis; fishing other genes or proteins which have a biological relationship with the known marker gene from biological big data by utilizing the known marker gene, and limiting the range to the genes which can be expressed by heart tissues to construct a specific myocardial fibrosis pathological gene module; constructing a drug data set with transcriptomics data, and obtaining drug transcriptomics data; predicting the anti-myocardial fibrosis capability of the corresponding drug according to the transcriptional spectrum data of the drug by adopting a gene expression deduction method, and screening therequired drug according to the anti-myocardial fibrosis capability of the drug. On the basis of different interactions of the myocardial fibrosis marker gene and other genes, a tissue-specific myocardial fibrosis module is constructed, anti-myocardial fibrosis potential drugs are screened through a computer, the batch screening is conducted, the accuracy is improved, the efficiency is high, and the cost is low.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a screening method for anti-myocardial fibrosis drugs. Background technique [0002] Myocardial fibrosis refers to the excessive accumulation of collagen fibers in the normal tissue structure of the myocardium, the significant increase of collagen concentration in cardiac tissue, or the change of collagen composition. These changes often seriously affect the function of the heart, leading to the occurrence of various cardiovascular diseases and eventually progressing to heart failure. Anti-myocardial fibrosis is one of the key therapeutic strategies to improve various cardiovascular diseases, but its drug development is mainly based on scattered research on related targets and lacks systemicity. [0003] So far, many marker genes of myocardial fibrosis have been discovered, such as periostin (POSTN), platelet-derived growth factor receptor α (PDGFRA), discoid domain receptor 2 ...

AI Technical Summary

Problems solved by technology

For another example, the difference in expression of many genes may not be very large, but the effect is obvious, and will be screened out by the pre-set difference multiple standard (such as difference multiple >2, etc.); it is difficult to screen in large quantities, with low efficiency and poor accuracy. Greatly increase the cost of later test verification

Images